Bilateral endophthalmitis following bilateral same‐day anti‐VEGF injections

Sepetis, Anastasios; Clarke, Benjamin; Gupta, Bhaskar

doi:10.1111/aos.14504

Cited by 3 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We avoided bilateral IVI in the same sitting because there have been incidences of bilateral endophthalmitis following bilateral anti-VEGF injections. 48 It is also reported that the cumulative rate of infective endophthalmitis increases with the number of IVI. 49 Therefore, it is a wise step to inject fellow eye a day later than to have bilateral IVI and devastating bilateral endophthalmitis.…”

Section: Discussionmentioning

confidence: 96%

Profile of Patients Treated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections in Bhutan

Bahadur¹,

Rai²,

Maddess³

2023

OPTH

View full text Add to dashboard Cite

Purpose Ocular vascular diseases are common causes of visual impairment and blindness, for which anti-vascular endothelial growth factor (anti-VEGF) is the first-line therapy. Current study describes the profile of patients receiving intravitreal anti-VEGF injections (IVI), and gender variation in Bhutan. The study was designed to inform national health policy. Study Design Retrospective cross-sectional study. Methods We reviewed the surgical registers of the vitreoretinal (VR) units across Bhutan over three years. Patient demography, clinical findings, diagnostic tests performed, and diagnoses or indications for IVI were logged. A descriptive analysis was performed. Results Despite limited availability of anti-VEGF, a total of 381 patients received IVI in operating theatres as mandated by the national guidelines. The majority of patients were males (230, 60.4%, p = 0.004). The mean age was 65.2 ± 13.5 years (range 13 years to 90 years), and a median of 69 years. The majority of the treated eyes (117, 30.7%) had BCVA <3/60 to light perception (PL), and another 51 eyes (13.4%) had < 6/60 to 3/60. The most common indication for IVI was neovascular age-related macular degeneration (nAMD) (168 cases, 42.2%), followed by retinal vein occlusion (RVO) (132 cases, 34.6%), diabetic macular oedema (DMO) and retinopathy (DR) (50 cases, 13.1%), and myopic choroidal neovascular membrane (11 cases, 0.03%). Conclusion Limited human resources for managing VR diseases in Bhutan are compounded by economic and geographic challenges. With increasing VR diseases such as nAMD and myopia and complications of systemic diseases such as DR, DMO and RVO, there is a need to improve VR services. Currently, anti-VEGF is procured only for a pooled patients requiring IVI, and patients are lost due to longer waiting periods. Bhutan needs to assess if females are reporting less or are not receiving treatment due to cultural barriers and social stigma.

show abstract

Section: Discussionmentioning

confidence: 96%

Profile of Patients Treated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections in Bhutan

Bahadur¹,

Rai²,

Maddess³

2023

OPTH

View full text Add to dashboard Cite

show abstract

“…However, in such cases, complications have grave effects. In one study, simultaneous bilateral injections were found to be safe [12], while in another study, bilateral IVT anti-VEGF injection resulted in bilateral endophthalmitis after two days [13]. In a series of 1418 bilateral same-day IVT anti-VEGF injections, no case of endophthalmitis was encountered [14].…”

Section: Discussionmentioning

confidence: 99%